This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation, Editing/proofreading
Expertise
Specializes in:
Biology (-tech,-chem,micro-)
Science (general)
Chemistry; Chem Sci/Eng
Genetics
Medical (general)
Medical: Pharmaceuticals
Rates
English to Portuguese - Standard rate: 0.08 USD per word / 20 USD per hour
English to Portuguese: Tysabri - Risk Management Plan 14- July 2012 General field: Science Detailed field: Medical: Pharmaceuticals
Source text - English Natalizumab is a recombinant humanised anti-α4-integrin antibody
produced in a murine cell line by recombinant DNA technology.
Natalizumab is a selective adhesion-molecule inhibitor and binds to
the α4-subunit of human integrins, which is highly expressed on the
surface of all leukocytes, with the exception of neutrophils.
Specifically, natalizumab binds to the α4β1 integrin, blocking the
interaction with its cognate receptor, vascular cell adhesion
molecule-1 (VCAM-1), and ligands osteopontin, and an alternatively
spliced domain of fibronectin, connecting segment-1 (CS-1).
Natalizumab blocks the interaction of α4β7 integrin with the
mucosal addressin cell adhesion molecule-1 (MadCAM-1).
Disruption of these molecular interactions prevents transmigration of
mononuclear leukocytes across the endothelium into inflamed
parenchymal tissue. A further mechanism of action of natalizumab
may be to suppress ongoing inflammatory reactions in diseased
tissues by inhibiting the interaction of α4-expressing leukocytes with
their ligands in the extracellular matrix and on parenchymal cells.
As such, natalizumab may act to suppress inflammatory activity
present at the disease site, and inhibit further recruitment of immune
cells into inflamed tissues.
Translation - Portuguese Natalizumabe é um anticorpo anti-α4-integrina humanizado recombinante produzido em uma célula murina por tecnologia de DNA recombinante. Natalizumabe é um inibidor seletivo de adesão molecular e se liga à subunidade α4 das integrinas humanas, que é altamente expressada na superfície de todos os leucócitos, com exceção dos neutrófilos. Especificamente, natalizumabe se liga à integrina α4β1, bloqueando a interação com seus receptores cognatos, molécula de adesão das células vasculares-1 (VCAM-1), e ligantes osteopontina, e um domínio dividido alternadamente de fibronectina, segmento de conexão-1 (CS-1). Natalizumabe bloqueia a interação da integrina α4β1 com a molécula de adesão das células da mucosa-1 (MadCAM-1). A interrupção dessas interações moleculares previne a transmigração dos leucócitos mononucleares para o endotélio no tecido parenquimal inflamado. Um mecanismo de ação adicional de natalizumabe pode ser suprimir as reações inflamatórias em andamento nos tecidos doentes pela inibição da interação dos leucócitos que expressam α4 com seus ligantes na matriz extracelular e nas células parenquimais. Sendo assim, o natalizumabe pode atuar na supressão da atividade inflamatória presente no local da doença, e inibir um recrutamento adicional de células imunes nos tecidos inflamados.
More
Less
Experience
Years of experience: 15. Registered at ProZ.com: Jan 2013.
I'm a professional translator and proofreader since 2009. I have a Biology degree and an ongoing graduation in Pharmacy. Medical, pharmaceutical and general science texts are my main experience. English to Portuguese (Brazil) translation is my specialty.
Keywords: English to Portugese (Brazilian), medical, pharmaceutical, general science, TRADOS 2017, MemoQ, Xbench, Translation Workspace